Journal Article
B. C Creech, Jimenez-Truque, N., Kown, N., Sokolow, K., Brady, E. J., Yoder, S., Solovay, K., Rubin, K., Noviello, S., Hensel, E., Selamawi, S., Bakare, A., Makowski, M., and Lu, K.,
“Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults”,
Vaccine, vol. 40, no. 47, pp. 6740-6746, 2022.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E.,
“Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.”,
PLoS One, vol. 14, no. 9, p. e0222178, 2019.
R. B. Belshe, Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., Wald, A., Poland, G., Jacobson, R., Keyserling, H. L., Spearman, P., Hill, H., and Wolff, M.,
“Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”,
J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
F. Nakwagala, Birungi, J., Schmidt, C., Nanvubya, A., Konde, C., Hughes, P., Mugisha, E., Johnson, B., Muluubya, A., Nielsen, L., Gilmour, J., Gibiansky, L., Smith, C., Fast, P., and Kaleebu, P.,
“Safety and immunogenicity of HIV-1 clade A vaccines in healthy, HIV uninfected adult Ugandan volunteers”, 2004.
S. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A., Rinella, P., Hill, H., Wolff, M., Schultze, V., Han, J., Scharschmidt, B., and Belshe, R.,
“Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults”,
Vaccine, vol. 28, pp. 6367-6373, 2010.
S. E. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A. M., Rinella, P., Hill, H., Wolff, M. C., Schultze, V., Han, J. H., Scharschmidt, B., and Belshe, R. B.,
“Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.”,
Vaccine, vol. 28, no. 38, pp. 6367-73, 2010.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I.,
“Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.”,
J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
H. Kibuuka, Berkowitz, N., Millard, M., Enama, M., Tindikahwa, A., Sekiziyivu, A., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L., Bailer, R., Koup, R., Nabel, G., ,, Robb, M., Ledgerwood, J., and Team, T. R. V. 247 Stu,
“Safety and Immunogenicity of Ebola Virus and Marburg Virus Glycoprotein DNA Vaccines Assessed Separately and Concomitantly in Healthy Ugandan Adults: A Phase 1b, Randomised, Double-Blind, Placebo-Controlled Clinical Trial”,
Lancet, vol. 385, pp. 1545-1554, 2015.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E.,
“Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.”,
Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
U. N. Sarwar, Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Sullivan, N. J., Graham, B. S., and Ledgerwood, J. E.,
“Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.”,
J Infect Dis, vol. 211, no. 4, pp. 549-57, 2015.
U. Sarwar, Costner, P., Enama, M., Berkowitz, N., Hu, Z., Hendel, C., Sitar, S., Plummer, S., Mulangu, S., Bailer, R., Koup, R., Mascola, J., Nabel, G., Sullivan, N., Graham, B., Ledgerwood, J. E., and Team, T. V. R. C. 206 St,
“Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial”,
J Infect Dis, vol. 211, pp. 549-557, 2015.
F. Scaggs Huang, Bernstein, D. I., Slobod, K. S., Portner, A., Takimoto, T., Russell, C. J., Meagher, M., Jones, B. G., Sealy, R. E., Coleclough, C., Branum, K., Dickey, M., Buschle, K., McNeal, M., Makowski, M., Nakamura, A., and Hurwitz, J. L.,
“Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.”,
Hum Vaccin Immunother, vol. 17, no. 2, pp. 554-559, 2021.
J. J. Treanor, Campbell, J., Zangwill, K. M., Rowe, T., and Wolff, M. C.,
“Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine”,
N Engl J Med, vol. 354, pp. 1343-1351, 2006.
J. J. Treanor, Campbell, J. D., Zangwill, K. M., Rowe, T., and Wolff, M.,
“Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.”,
N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H.,
“Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given Without or With Aluminum Hydroxide to Healthy Adults: Results of a Phase I-II Randomized Clinical Trial”,
J Infec Dis, vol. 198, pp. 1309-1316, 2009.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H.,
“Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”,
J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
K. Modjarrad, Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M. - D., Lamarre, C., Zaidi, F. I., Boyer, J., Kudchodkar, S. B., Jeong, M., Darden, J. M., Park, Y. K., Scott, P. T., Remigio, C., Parikh, A. P., Wise, M. C., Patel, A., Duperret, E. K., Kim, K. Y., Choi, H., White, S., Bagarazzi, M., May, J. M., Kane, D., Lee, H., Kobinger, G., Michael, N. L., Weiner, D. B., Thomas, S. J., and Maslow, J. N.,
“Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.”,
Lancet Infect Dis, vol. 19, no. 9, pp. 1013-1022, 2019.
G. C. Paulsen, Frenck, R., Tomashek, K. M., Alarcon, R. M., Hensel, E., Lowe, A., Brocato, R. L., Kwilas, S. A., Josleyn, M. D., and Hooper, J. W.,
“Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: a Randomized, Controlled Phase 1 Study.”,
J Infect Dis, 2023.
M. A. Thera, Doumbo, O. K., Coulibaly, D., Laurens, M. B., Kone, A. K., Guindo, A. B., Traore, K., Sissoko, M., Diallo, D. A., Diarra, I., Kouriba, B., Daou, M., Dolo, A., Baby, M., Sissoko, M. S., Sagara, I., Niangaly, A., Traore, I., Olotu, A., Godeaux, O., Leach, A., Dubois, M. - C., W Ballou, R., Cohen, J., Thompson, D., Dube, T., Soisson, L., Diggs, C. L., Takala, S. L., Lyke, K. E., House, B., Lanar, D. E., Dutta, S., D Heppner, G., and Plowe, C. V.,
“Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.”,
PLoS One, vol. 5, no. 2, p. e9041, 2010.
M. Thera, Doumbo, O., Coulibaly, D., Laurens, M., Kone, A., Guindo, A., Traore, K., Sissoko, M., Diallo, D., Diarra, I., Kouriba, B., Daou, M., Dolo, A., Baby, M., Sissoko, M., Sagara, I., Niangaly, A., Traore, I., Olotu, A., Godeaux, O., Leach, A., Dubois, M., and Ballou, W.,
“Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial”,
PLoS One, vol. 5, p. e9041, 2010.
H. M. El Sahly, Atmar, R. L., Patel, S. M., Bellamy, A., Liu, L., Hong, W., Zhu, H., Guan, Y., and Keitel, W. A.,
“Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.”,
Vaccine, vol. 37, no. 19, pp. 2561-2568, 2019.
K. E. Stephenson, Tan, C. Sabrina, Walsh, S. R., Hale, A., Ansel, J. L., Kanjilal, D. G., Jaegle, K., Peter, L., Borducchi, E. N., Nkolola, J. P., Makoni, T., Fogel, R., Bradshaw, C., Tyler, A., Moseley, E., Chandrashekar, A., Yanosick, K. E., Seaman, M. S., Eckels, K. H., De La Barrera, R. A., Thompson, J., Dawson, P., Thomas, S. J., Michael, N. L., Modjarrad, K., and Barouch, D. H.,
“Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.”,
Lancet Infect Dis, vol. 20, no. 9, pp. 1061-1070, 2020.
E. E. Coates, Edupuganti, S., Chen, G. L., Happe, M., Strom, L., Widge, A., Florez, M. Burgos, Cox, J. H., Gordon, I., Plummer, S., Ola, A., Yamshchikov, G., Andrews, C., Curate-Ingram, S., Morgan, P., Nagar, S., Collins, M. H., Bray, A., Nguyen, T., Stein, J., Case, C. L., Kaltovich, F., Wycuff, D., C Liang, J., Carlton, K., Vazquez, S., Mascola, J. R., and Ledgerwood, J. E.,
“Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.”,
Lancet Infect Dis, vol. 22, no. 8, pp. 1210-1220, 2022.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., Hill, H. R., and Group, T. V. T. E. U. - H. 3Nv,
“Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old”,
J Infect Dis, vol. 212, pp. 552-561, 2015.
]